NCT00333216View on ClinicalTrials.gov

Anecortave Acetate Risk-Reduction Trial (AART)

PHASE3TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
AMD
Interventions
DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Posterior juxtascleral administration of suspension

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/ML

Posterior juxtascleral administration of suspension

OTHER

Anecortave Acetate Vehicle

Sham posterior juxtascleral administration of suspension

Trial Locations (1)

76134

Contact Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) | Biotech Hunter | Biotech Hunter